US Patent

US9321807 — Crystal forms

Composition of Matter · Assigned to AbbVie Inc · Expires 2035-06-05 · 9y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects crystalline forms of Compound I, as shown in FIGS. 1-4 of the patent.

USPTO Abstract

The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of FIGS. 1 - 4.

Drugs covered by this patent

Patent Metadata

Patent number
US9321807
Jurisdiction
US
Classification
Composition of Matter
Expires
2035-06-05
Drug substance claim
Yes
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.